Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?.
- Author:
Ji Sun BAEK
1
;
Wan Ho LEE
;
Woo Dae KANG
;
Seok Mo KIM
Author Information
- Publication Type:Original Article
- Keywords: Endometrial hyperplasia; Endometrial cancer; Fertility; Progestins
- MeSH: Appointments and Schedules; Biopsy; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms*; Female; Fertility; Fertility Preservation; Follow-Up Studies; Humans; Hyperplasia*; Hysterectomy; Magnetic Resonance Imaging; Medical Records; Mortuary Practice; Progestins; Prospective Studies; Recurrence
- From:Obstetrics & Gynecology Science 2016;59(1):24-31
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: The aim of this study is to assess the effectiveness of oral progestin treatment in women diagnosed with complex atypical hyperplasia (CAH) or grade 1 endometrial cancer (G1EC), who desire to preserve their fertility, as alternative treatment to a hysterectomy. METHODS: We reviewed the medical records of women younger than 45 years old that had been diagnosed with CAH or G1EC, who expressed a desire to preserve their fertility using alternative treatment at our institution. Women without evidence of myometrial invasion on pelvic magnetic resonance imaging scans were included. The study period was between 2004 and 2014. Endometrial biopsies were taken at follow-up appointments. RESULTS: We identified 31 young women with CAH or G1EC. The median age was 33 years old (range, 20 to 41), and the median period of time undertaking the treatment was 5 months (range, 1 to 12). Twenty-three patients (74.2%) achieved complete remission (CR; median time to CR was 3 months; range, 1 to 22), 16 patients (88.9%) with CAH and 7 (53.8%) with G1EC achieved CR. 6 patients (26.1%) who had achieved CR, had recurrence of the disease (median time from CR to recurrence was 12.5 months; range, 4 to 18). Eight patients (25.8%) finally underwent a hysterectomy. CONCLUSION: Oral progestin therapy is an alternative treatment for women with CAH or G1EC who desire fertility preservation. However, more prospective studies are needed for standard progestin regimen. Also, there still remains a risk of disease progression and recurrence. Therefore, close follow-up is important during treatment and after CR. In addition, a hysterectomy is recommended as a definitive treatment after completion of childbearing.
